我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

扶正中药在乳腺癌新辅助治疗中的意义*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2018年03期
页码:
47
栏目:
临床研究
出版日期:
2018-12-15

文章信息/Info

Title:
Significance of Fuzheng Chinese Medicine Combined with Neoadjuvant Chemotherapy in Breast Cancer
作者:
盛佳钰刘钰严兆霞江科
(上海中医药大学附属岳阳中西医结合医院乳腺病科,上海 200437)
Author(s):
SHENG Jiayu LIU Yu YAN Zhaoxia JIANG Ke
(Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China)
关键词:
乳腺肿瘤 新辅助化疗 P-糖蛋白 扶正中药
Keywords:
breast cancer neoadjuvant chemotherapy P-glycoprotein Fuzheng Chinese medicine
分类号:
R273
DOI:
10.19288/j.cnki.issn.1000-2723.2018.03.010
文献标识码:
A
摘要:
目的观察扶正中药联合新辅助化疗在乳腺癌中的临床疗效。方法随机将可手术乳腺癌分成单纯化疗组及中药联合化 疗组,观察2组间的临床及病理疗效,及P-糖蛋白(P-gp)在2组间的表达差异。结果102例患者中,单纯化疗组与联合组在 临床疗效上无差别,但在病理疗效差别有统计学意义,P-gp阳性患者病理缓解不明显,联合组经新辅助治疗后P-gp的转阳 率较单纯化疗组少,差异有统计学意义。结论P-gp的表达对于化疗疗效具有一定的预测作用,扶正中药可能通过P-gp途径 ,有逆转化疗耐药的作用,同时提高了新辅助化疗的病理缓解率。
Abstract:
Objective To investigate the effect of Fuzheng Chinese medicine combined with neoadjuvant chemotherapy in breast cancer. Methods We randomized operable breast cancer into chemotherapy group and Chinese medicine combined with chemotherapy group. The clinical and pathological effects, and expression of P-glycoprotein(Pgp)were observed between two groups. Results There was no difference in clinical effect between two groups. However, statistical difference existed in pathological effect. No significant pathological response was observed in Pgp-positive patients. The positive rates of Pgp was less in the combined group than that in the chemotherapy group. Statistical significance existed between two groups. Conclusion The expression of Pgp has a predictive effect on chemotherapy effect. Fuzheng Chinese medicine may reverse chemotherapy resistance through Pgp pathway. And it also improves the pathological response rate of neoadjuvant chemotherapy.

参考文献/References


[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics,2016[J]. CA Cancer J Clin,2016,66(1):7-30.
[2] 王怀璋,王迎红,陈金秀,等. 墓头回总甙片治疗大肠癌的临床观察[J]. 中国肿瘤临床与康复,2001(1):3.
[3] 戈士文,张艳,腊胜明,等. 气血葆口服液与阿霉素合用对荷瘤小鼠化疗的增效作用[J]. 河南中医,2000,20(3) :20-21.
[4] CHARFARE H, LIMONGELLI S, PURUSHOTHAM A D. Neoadjuvant chemotherapy in breast cancer[J]. Br J Surg, 2005,92(1):14-23.
[5] 吴家豪,何劲松,倪勇,等. 乳腺癌新辅助化疗疗效评价方法进展[J]. 癌症,2010,29(2):240-244.
[6] VON M G, RAAB G, CAPUTO A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group[J]. J Clin Oncol,2005,23(12):2676-2685.
[7] GIANNI L, EIERMANN W, SEMIGLAZOV V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer(the NOAH trial):a randomised controlled superiority trial with a parallel HER2-negative cohort[J]. Lancet,2010,375(9712):377-384.
[8] 刘海鸥,张喜平. 乳腺癌新辅助化疗的研究进展[J]. 医学综述,2014,20(4):653-656.
[9] CHEN K G, SIKIC B I. Molecular pathways:regulation and therapeutic implications of multidrug resistance[J]. Clin Cancer Res,2012,18(7):1863-1869.
[10] LEEUWEN F W, BUCKLE T, KERSBERGEN A, et al. Noninvasive functional imaging of P-glycoprotein- mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response,and assign P-gp inhibitor sensitivity[J]. Eur J Nucl Med Mol Imagong,2009,36(3):406-412.
[11] GUPTA P, GARG T, TANMAY M, et al. Polymeric Drug-Delivery Systems:Role in P-gp Ef ux System Inhibition[J]. Crit Rev Ther Drug Carrier Syst,2015,32(3):247-275.
[12] ZHU Y, LIU C, NADIMINTY N, et al. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer[J]. Mol Cancer Ther,2013,12(9):1829-1836.
[13] 李沫函,何文婷,张洪亮. 四君子汤益气健脾抗肿瘤临床研究进展[J]. 新疆中医药,2013,31(1):77-78.
[14] 吴继. 刘嘉湘扶正法治疗恶性肿瘤经验[J]. 辽宁中医杂志,2010,37(6):992-993.
[15] 陈日辉,冯海都. 中医抗癌扶正法治疗恶性肿瘤的临床价值[J]. 中国医学创新,2016,13(25):27-29.
[16] 刘水军,杨亚琴. 中医扶正当贯穿恶性肿瘤治疗始终[J]. 中医临床研究,2014,6(11):56-57.
[17] 瞿文超,吴雪卿,冯佳梅,等. 中药复方对不同分子分型乳腺癌患者无病生存率及总生存率的影响[J]. 中医药学报 ,2017,45(6):92-95.
[18] 周东波,胡成平,苏晓丽,等. 人参单体Rh2诱导人肺腺癌A549/DDP细胞凋亡的体外研究[J]. 中国肺癌杂志,2005, 8(4):257-260.
[19] 张隽开,王忠裕,丁大朋,等. 黄芪对肝癌耐药细胞株Bel/Fu化疗敏感性的影响[J]. 中国中西医结合外科杂志, 2008,14(4):398-402.
[20] 吴剑锋,何晓东,许卫东,等. 淫羊藿苷逆转耐甲氨蝶呤肺癌A549细胞转移表型[J]. 肿瘤,2009,29(12):1124 -1128.

备注/Memo

备注/Memo:
收稿日期: 2018 - 06- 03 *
基金项目: 上海市卫计委科研项目(201540234,2018LQ020);上海市科委科研计划项目(17401935300)
第一作者简介: 盛佳钰(1983-),女,博士,主治医师,研究方向:中医药防治乳腺癌。
△通信作者: 江科,E-mail:surgeonjk@163.com
更新日期/Last Update: 2018-12-30